Welcome to our dedicated page for Atea Pharmaceuticals SEC filings (Ticker: AVIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Atea Pharmaceuticals SEC filings document the regulatory record of a Nasdaq-listed clinical biopharmaceutical company developing oral antiviral therapies. Form 8-K reports furnish financial results, preliminary financial information, business updates, and exhibit press releases that describe the company’s HCV and HEV antiviral programs.
Proxy and annual meeting filings cover governance matters, director elections, auditor ratification, executive compensation, pay-versus-performance disclosures, and stockholder voting results. The filings also identify Atea’s common stock, par value $0.001 per share, traded under AVIR on The Nasdaq Global Select Market.
Atea Pharmaceuticals is a late-stage antiviral developer reporting continued operating losses while advancing its HCV and HEV programs. For the three months ended June 30, 2026, it recorded a net loss of $32.9 million compared with $37.2 million a year earlier; for the first six months, the net loss was $78.4 million.
Cash, cash equivalents and marketable securities totaled $219.5 million as of June 30, 2026, which the company believes will fund planned operations through 2027, including completion of its Phase 3 HCV program. Second-quarter research and development expense was $28.2 million and general and administrative expense was $6.9 million, with G&A down year over year.
The lead HCV regimen, a fixed-dose combination of bemnifosbuvir and ruzasvir (BEM/RZR), achieved statistical non-inferiority to sofosbuvir/velpatasvir in the Phase 3 C-BEYOND trial, including a 93.9% sustained virologic response rate in the modified intent-to-treat population. Enrollment in the second Phase 3 trial, C-FORWARD, is complete, with topline data expected early in the first quarter of 2027 and an FDA New Drug Application targeted for the second quarter of 2027 if results are positive. Atea also initiated a Phase 1 trial of AT-587 for hepatitis E virus and maintains an unused $200 million at-the-market equity facility.
Atea Pharmaceuticals reported second quarter 2026 results and a major clinical milestone. The Phase 3 C-BEYOND trial of bemnifosbuvir/ruzasvir (BEM/RZR) for hepatitis C met its primary and secondary endpoints in a real-world-like North American population, supporting a potential best-in-class, 8‑week regimen for most non‑cirrhotic patients. A second Phase 3 trial, C-FORWARD, completed enrollment of more than 880 patients across 17 countries, with topline data expected in early Q1 2027 and a potential US NDA submission for BEM/RZR targeted for Q2 2027.
For the quarter ended June 30, 2026, Atea reported a net loss of $32.9 million, compared with $37.2 million a year earlier, as operating expenses declined. Research and development expense was $28.2 million versus $32.3 million, and general and administrative expense was $7.0 million versus $9.1 million, reflecting lower stock-based compensation and professional fees. Cash, cash equivalents and marketable securities were $219.5 million at June 30, 2026, down from $301.8 million at December 31, 2025, with working capital of $200.5 million and no debt-like liabilities indicated.
Atea also initiated a first‑in‑human Phase 1 trial of AT-587 for chronic hepatitis E in immunocompromised patients, addressing an area with no approved antiviral therapies and significant unmet medical need.
Atea Pharmaceuticals director Bruno Lucidi reported equity compensation activity centered on stock awards rather than open‑market trades. He exercised 29,600 restricted stock units into Common Stock and held 142,350 Common shares directly afterward. He also received 37,700 stock options with a $4.36 exercise price and 26,700 new restricted stock units, all subject to time‑based vesting over the coming year.
Atea Pharmaceuticals director Franklin M. Berger increased his equity exposure through compensation-related awards and an RSU vesting event. On June 18, 2026, 29,600 restricted stock units converted into an equal number of common shares, bringing his direct common stock holdings to 536,097 shares.
He also received a stock option for 37,700 shares at an exercise price of $4.36 per share, vesting in twelve equal monthly installments after June 18, 2026, and expiring on June 17, 2036. In addition, he was granted 26,700 new restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Atea Pharmaceuticals director Howard Berman received new equity awards as part of his compensation. On June 18, 2026, he was granted stock options covering 37,700 shares of common stock at an exercise price of $4.36 per share. These options vest in twelve substantially equal monthly installments after June 18, 2026, and are fully vested on June 18, 2027, if he continues serving the company.
He also received 26,700 restricted stock units, each representing a contingent right to one share of common stock. The RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Atea Pharmaceuticals director Barbara Gayle Duncan increased her equity stake through routine compensation-related transactions. On June 18, 2026, previously granted restricted stock units converted into 29,600 shares of common stock, bringing her direct holdings to 92,350 shares.
She also received new grants covering 37,700 stock options with a $4.36 exercise price, vesting in twelve equal monthly installments through June 18, 2027, and 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to continued service.
Atea Pharmaceuticals director Bruce Polsky reported routine equity compensation changes. On June 18, 2026, he exercised 29,600 restricted stock units into Common Stock at no cost, bringing his direct Common Stock holdings to 124,806 shares.
He also received new awards: a stock option for 37,700 shares of Common Stock at an exercise price of $4.36 per share, vesting in twelve equal monthly installments after June 18, 2026, and 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, in each case subject to continued service. The filing shows no share sales, only grants and exercises related to compensation.
Atea Pharmaceuticals director Polly A. Murphy reported equity compensation activity and an RSU vesting-related share delivery. On June 18, 2026, RSUs covering 29,600 shares of common stock were exercised into common stock, leaving her with 121,745 common shares directly held.
On the same date, she received a stock option grant for 37,700 shares of common stock at an exercise price of $4.36 per share, vesting in twelve substantially equal monthly installments through June 18, 2027, and expiring on June 17, 2036. She was also granted 26,700 restricted stock units, each representing one share of common stock, vesting in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to continued service.
Atea Pharmaceuticals director Jerome M. Adams reported equity compensation and a routine derivative exercise. On June 18, 2026, he exercised 29,600 shares of previously granted restricted stock units into Common Stock, leaving him with 92,350 Common shares held directly.
On the same date, he received a new grant of 37,700 stock options with a $4.36 exercise price, expiring on June 17, 2036, which vest in twelve equal monthly installments after June 18, 2026. He was also granted 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Atea Pharmaceuticals director Arthur S. Kirsch received new equity awards. He was granted stock options covering 37,700 shares of common stock at an exercise price of $4.36 per share. These options vest in twelve substantially equal monthly installments after June 18, 2026 and are fully vested by June 18, 2027, subject to his continued service.
Kirsch also received 26,700 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, conditioned on continued service through the vesting date.